Silibinin inhibits ethanol metabolism and ethanol-dependent cell proliferation in an in vitro model of hepatocellular carcinoma.
about
Differential in vitro effects of intravenous versus oral formulations of silibinin on the HCV life cycle and inflammation.Data mining reveals complex interactions of risk factors and clinical feature profiling associated with the staging of non-hepatitis B virus/non-hepatitis C virus-related hepatocellular carcinoma.Altered expression and function of regulator of G-protein signaling-17 (RGS17) in hepatocellular carcinomaAlcohol induces liver neoplasia in a novel alcohol-preferring rat modelChronic ethanol feeding accelerates hepatocellular carcinoma progression in a sex-dependent manner in a mouse model of hepatocarcinogenesis.Behavioral and Neurochemical Deficits in Aging Rats with Increased Neonatal Iron Intake: Silibinin's Neuroprotection by Maintaining Redox Balance.Silibinin (Milk Thistle) potentiates ethanol-dependent hepatocellular carcinoma progression in male miceAntimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer.Targeting collagen expression in alcoholic liver disease.Herbal Medicine Offered as an Initiative Therapeutic Option for the Management of Hepatocellular Carcinoma.Silibinin: a potential old drug for cancer therapy.Diet-induced obesity and ethanol impair progression of hepatocellular carcinoma in a mouse mesenteric vein injection model.Evaluation of a bioresorbable drug delivery system for the treatment of hepatocellular carcinoma.Inhibition of silibinin on migration and adhesion capacity of human highly metastatic breast cancer cell line, MDA-MB-231, by evaluation of β1-integrin and downstream molecules, Cdc42, Raf-1 and D4GDI.Silibinin Prevents Autophagic Cell Death upon Oxidative Stress in Cortical Neurons and Cerebral Ischemia-Reperfusion Injury.Altered fatty acid-binding protein 4 (FABP4) expression and function in human and animal models of hepatocellular carcinoma.Use of a crossed high alcohol preferring (cHAP) mouse model with the NIAAA-model of chronic-binge ethanol intake to study liver injury.Evaluation of HepaRG cells for the assessment of indirect drug-induced hepatotoxicity using INH as a model substance.
P2860
Q30997889-18AADC8F-F98B-4FC3-BDD2-C88D7F63831BQ33875631-16F93571-BAA0-4B67-B07A-8443265963FBQ35222525-11E4B989-3A7B-4ECB-8DD9-92191B1A0D29Q35478720-E6A7F195-5867-46F3-A6A8-446AF430C70EQ35783979-73271FBB-9218-43F7-9579-4F67C8ABC03FQ36215968-2B2030FB-06AE-4678-9877-72FE08410C18Q36254212-054CFFC2-FC4E-40E6-8D22-F88B9F9CCD92Q37591742-26CCFE77-E2B8-45CB-BF20-6A26428176CAQ37883929-0D8E5A43-2E98-40AE-A43F-7BA7E8781AACQ38734645-1BD25AE5-F8A7-4848-99AB-7FF40A1CD957Q38881726-C1D800D8-EB4A-4ADB-B454-ED77287894FFQ39312976-71097CEA-31B3-46D3-B5FB-6A5695AC5D74Q39439093-97664113-FCB9-480C-ABBC-A10B62013CB2Q39439840-4057A396-8717-44F3-97FD-3EF576E0DFCBQ41621554-B0D7DB55-E9D3-41CC-8F79-B567B170C68FQ47368821-924B809B-BC51-41FC-A1BB-B3767C683EC5Q47785930-7E8138A9-663A-4AA5-BF1B-81186B513F4DQ52644322-64DA420D-3FB8-49AE-B240-34B6C1AB091E
P2860
Silibinin inhibits ethanol metabolism and ethanol-dependent cell proliferation in an in vitro model of hepatocellular carcinoma.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Silibinin inhibits ethanol met ...... l of hepatocellular carcinoma.
@en
Silibinin inhibits ethanol met ...... l of hepatocellular carcinoma.
@nl
type
label
Silibinin inhibits ethanol met ...... l of hepatocellular carcinoma.
@en
Silibinin inhibits ethanol met ...... l of hepatocellular carcinoma.
@nl
prefLabel
Silibinin inhibits ethanol met ...... l of hepatocellular carcinoma.
@en
Silibinin inhibits ethanol met ...... l of hepatocellular carcinoma.
@nl
P2093
P2860
P1433
P1476
Silibinin inhibits ethanol met ...... l of hepatocellular carcinoma.
@en
P2093
Elizabeth Brandon-Warner
Iain H McKillop
James A Sugg
Laura W Schrum
P2860
P304
P356
10.1016/J.CANLET.2009.10.004
P407
P577
2009-11-08T00:00:00Z